Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28439)	3/9/1999 9:12:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< LGND in single digits is absurdly cheap. >> Henry, you used to have revenue estimates going out several years. Is it possible for you to get updated estimates, based on the delay in the Lilly diabetes program? If LGND is as absurdly cheap as you say, I would think that you would have some reference to possible future sales levels, or, perhaps a LGND stock evaluation based on future estimated sales. It's one thing to have great science, but it must be effectively funded and brought to market. TIA, Bob